Comparative pharmacokinetics of four bioactive components in normal and chronic heart failure rats after oral administration of Qiangxin Lishui Prescription by microdialysis combined with ultra‐high‐performance liquid chromatography

Abstract

Qiangxin Lishui Prescription (QLP) has been clinically applied for treating heart failure with remarkable curative effects. A multi‐component pharmacokinetic research is very necessary for determining active substances in it. This study aims to profile the traits and differences in the pharmacokinetics of salvianolic acid B, astragaloside IV, calycosin‐7‐O‐β‐D‐glucoside and kaempferol in QLP between normal and chronic heart failure (CHF) rats by microdialysis combined with ultra‐high‐performance liquid chromatography‐tandem mass spectrometry (UHPLC‐MS/MS). Sensitive, selective, and online microdialysis combined with the UHPLC‐MS/MS method was successfully established and applied to study the pharmacokinetics of QLP. The pathological condition of CHF could lead to the enhancement of systematic exposure and reduction of the metabolic rate of four bioactive components for better bioavailability and therapeutic efficacy. The pharmacokinetic results will provide data support for the clinical application of QLP.